Stock MRK MERCK & CO., INC.
Add to a list

Merck & Co., Inc. Share Price

Equities

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse
Other stock markets
 02:30:20 06/12/2025 am IST 		After hours 04:30:11 am
99.72 USD -1.16% Intraday chart for Merck & Co., Inc. 99.79 +0.07%
06/12 Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns RE
05/12 Global markets live: Netflix, Visa, Airbus, Ferrovial, Leonardo… Zonebourse

Valuation: Merck & Co., Inc.

Capitalization 25TCr 21TCr 20TCr 19TCr 34TCr 22,27500Cr 37TCr 2,33100Cr 90TCr 10,52000Cr 93TCr 91TCr 38,46700Cr P/E ratio 2025 *
12.9x
P/E ratio 2026 * 13.4x
Enterprise value 27TCr 23TCr 22TCr 20TCr 38TCr 24,55600Cr 41TCr 2,57000Cr 99TCr 11,59700Cr 1,02400Cr 1,00200Cr 42,40500Cr EV / Sales 2025 *
4.21x
EV / Sales 2026 * 3.84x
Free-Float
70.67%
Yield 2025 *
3.24%
Yield 2026 * 3.39%
More valuation ratios * Estimated data

Chart: Merck & Co., Inc.

Dynamic Chart

Latest news: Merck & Co., Inc.

06/12 Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns RE
05/12 Global markets live: Netflix, Visa, Airbus, Ferrovial, Leonardo… Zonebourse
05/12 Health Rounds: Shingles vaccine reduces risk of death from dementia, study finds RE
05/12 Guggenheim Adjusts Price Target on Merck & Co. to $122 From $104, Maintains Buy Rating MT
07:27am Kennedy's advisers scrap hepatitis B vaccine guidance for most children in major policy shift RE
05/12 Halozyme Granted Injunction Against Merck & Co. in Germany in Keytruda Patent Case -- Update DJ
05/12 Halozyme Wins German Patent Injunction Blocking Merck's Subcutaneous Keytruda MT
05/12 Correction to Halozyme Granted Injunction Against Merck & Co. Article DJ
05/12 Halozyme Granted Injunction Against Merck & Co. in Germany in Keytruda Patent Case DJ
05/12 Halozyme wins preliminary injunction against Merck's Keytruda SC in Germany RE
04/12 Merck says Exzolt Cattle-CA1 to be available by prescription in Q1 2026 RE
04/12 Merck Gets Conditional FDA Approval for Cattle Antiparasitic DJ
04/12 Merck Animal Heath Gets FDA Conditional Approval for Exzolt Cattle-CA1 MT
More news

Last Transcript: Merck & Co., Inc.

Logo Merck & Co., Inc.
Merck & Co., Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-03-2025 01:00 PM
04/12
More transcripts

Analysts' recommendations: Merck & Co., Inc.

05/12 Guggenheim Adjusts Price Target on Merck & Co. to $122 From $104, Maintains Buy Rating MT
04/12 Scotiabank Adjusts Price Target on Merck & Co to $120 From $105, Maintains Sector Outperform Rating MT
01/12 Goldman Sachs Adjusts Price Target on Merck to $120 From $92, Maintains Buy Rating MT
24/11 Wells Fargo Upgrades Merck & Co. to Overweight From Equalweight, Adjusts PT to $125 From $90 MT
19/11 Berenberg Adjusts Price Target on Merck & Co. to $95 From $90, Maintains Hold Rating MT
More recommendations

Press Releases: Merck & Co., Inc.

04/12 FDA Conditionally Approves Merck Animal Health's EXZOLT™ CATTLE-CA1 for the Prevention and Treatment of New World Screwworm (Cochliomyia hominivorax) Larvae (myiasis) BU
01/12 Merck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025 BU
26/11 Merck to Participate in the Citi 2025 Global Healthcare Conference BU
26/11 Merck to Participate in the 8th Annual Evercore ISI HealthCONx Conference BU
24/11 Merck Data to be Presented at ASH 2025 Annual Meeting Showcase Continued Advancements in Hematology Pipeline and Novel Therapeutic Approaches BU
More press releases

News in other languages: Merck & Co., Inc.

05/12 Merck Animal Health obtient une approbation conditionnelle de la FDA
04/12 Formycon schließt erste Vermarktungspartnerschaft für Keytruda-Biosimilar
03/12 Avis d'analystes du jour : nouveaux avis positifs sur Veolia et Bayer, ArcelorMittal et Engie séduisent
03/12 Le bitcoin remet Wall Street dans le sens de la marche
02/12 Wall Street : Prêt ou pas, le compte à rebours est lancé
More news

Quotes and Performance

1 day-1.16%
1 week-4.87%
Current month-4.87%
1 month+18.17%
3 months+17.72%
6 months+28.47%
Current year+0.24%
More quotes

Course Extremes

1 week 99.19
Extreme 99.19
 105.68
1 month 85.24
Extreme 85.24
 105.84
Current year 73.31
Extreme 73.31
 105.84
1 year 73.31
Extreme 73.31
 105.84
3 years 73.31
Extreme 73.31
 134.63
5 years 70.89
Extreme 70.89
 134.63
10 years 47.97
Extreme 47.97
 134.63
More quotes

Managers and Directors: Merck & Co., Inc.

Manager TitleAgeSince
Robert Davis CEO
 Chief Executive Officer 58 01/07/2021
Caroline Litchfield DFI
 Director of Finance/CFO 56 01/04/2021
Dave Williams CTO
 Chief Tech/Sci/R&D Officer 56 01/08/2020
Director TitleAgeSince
Tom Glocer BRD
 Director/Board Member 65 27/11/2007
Patricia Russo BRD
 Director/Board Member 72 01/09/1995
Robert Davis CHM
 Chairman 58 01/12/2022
More insiders

ETFs: Merck & Co., Inc.

Name Weight AuM Varia. Jan 1. Investor
AGF U.S. MARKET NEUTRAL ANTI-BETA FUND - USD ETF AGF U.S. Market Neutral Anti-Beta Fund - USD
14.34% 303 M€ -21.21% -
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY ETF Nomura NEXT FUNDS International Equity MSCI-KOKUSAI (Yen-Hedged) ETF - JPY
5.61% 26 M€ +11.73% -
More ETFs: Merck & Co., Inc.

Other Pharmaceuticals

Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi.($)
MERCK & CO., INC. Stock Merck & Co., Inc.
-1.16%-4.87%-3.70%-9.35% 25TCr
ELI LILLY AND COMPANY Stock Eli Lilly and Company
-0.41%-6.06%+22.37%+173.58% 90TCr
JOHNSON & JOHNSON Stock Johnson & Johnson
-0.27%-2.41%+35.05%+12.95% 49TCr
ABBVIE INC. Stock AbbVie Inc.
-1.15%-0.71%+28.33%+37.90% 40TCr
ROCHE HOLDING AG Stock Roche Holding AG
+0.26%+1.14%+21.30%+0.44% 33TCr
ASTRAZENECA PLC Stock AstraZeneca PLC
+0.58%-2.73%+28.01%+20.71% 28TCr
NOVARTIS AG Stock Novartis AG
+0.19%+2.49%+18.48%+24.80% 26TCr
NOVO NORDISK A/S Stock Novo Nordisk A/S
+1.24%-2.33%-59.84%-31.25% 21TCr
AMGEN INC. Stock Amgen Inc.
-3.02%-4.51%+20.25%+15.79% 18TCr
GILEAD SCIENCES, INC. Stock Gilead Sciences, Inc.
-1.14%-3.67%+29.80%+37.78% 15TCr
Average -0.30%-2.37%+14.01%+28.34% 34.47TCr
Weighted average by Cap. -0.13%-2.83%+18.15%+55.19%
See all sector performances

Financials

2025 *2026 *
Net sales 6.48TCr 5.57TCr 5.22TCr 4.86TCr 8.98TCr 5,82900Cr 9.77TCr 61TCr 24TCr 2,75300Cr 24TCr 24TCr 10,06500Cr 6.82TCr 5.86TCr 5.49TCr 5.12TCr 9.46TCr 6,13800Cr 10TCr 64TCr 25TCr 2,89900Cr 26TCr 25TCr 10,60000Cr
Net income 1.95TCr 1.67TCr 1.57TCr 1.46TCr 2.7TCr 1,75200Cr 2.94TCr 18TCr 7.08TCr 83TCr 7.31TCr 7.15TCr 3,02600Cr 1.84TCr 1.58TCr 1.48TCr 1.38TCr 2.55TCr 1,65500Cr 2.77TCr 17TCr 6.69TCr 78TCr 6.9TCr 6.76TCr 2,85900Cr
Net Debt 2.53TCr 2.18TCr 2.04TCr 1.9TCr 3.51TCr 2,28100Cr 3.82TCr 24TCr 9.22TCr 1,07700Cr 9.51TCr 9.31TCr 3,93800Cr 1.47TCr 1.26TCr 1.18TCr 1.1TCr 2.03TCr 1,32100Cr 2.21TCr 14TCr 5.34TCr 62TCr 5.51TCr 5.39TCr 2,28100Cr
More financial data * Estimated data

Company Profile

Logo Merck & Co., Inc.
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.4%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (20%); - sale of animal health products (9.2%); - other (1.4%). Net sales are distributed geographically as follows: the United States (50.3%), Europe/Middle East/Africa (21.8%), Latin America (5.4%), China (8.6%), Japan (5.1%), Asia/Pacific (4.8%) and other (4%).
Employees
74,000
Sector
Pharmaceuticals
Calendar
15/12 - Ex-dividend day
More about the company

Quotes

Date Price Change Volume
05/25/05 99.72 $ -1.16% 1,64,30,388
04/25/04 100.89 $ -1.35% 1,27,70,712
03/25/03 102.27 $ +1.23% 1,25,41,641
02/25/02 101.03 $ -0.79% 1,17,94,980
01/25/01 101.83 $ -2.86% 1,41,78,308

Delayed Quote Nyse, December 06, 2025 at 02:30 am IST

More quotes

Income Statement and Estimates

More financial data

Ratings

Trader

Trader

This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Investor

Investor

This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Global

Global

This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.

Quality

Quality

This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.

ESG MSCI
A
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
99.72USD
Average target price
106.62USD
Spread / Average Target
+6.92%
Consensus
EPS Estimates
Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. MRK Stock

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States
United-States
Canada
Canada

MIDDLE EAST

Saudi Arabia
Saudi Arabia
United Arab Emirates
United Arab Emirates

EUROPE

France
France
Deutschland
Deutschland
Suisse
Suisse
Schweiz
Schweiz
Italia
Italia
Österreich
Österreich
België
België
Nederland
Nederland
España
España
Sverige
Sverige
United Kingdom
United Kingdom

APAC

Australia
Australia
India
India
Hong Kong
Hong Kong
United States

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition